Journal article icon

Journal article

Quantitative analysis predicts the relative therapeutic efficacy of different forms of CTLA4Ig.

Abstract:

Modulating the activities of costimulatory molecules controlling immune responses holds considerable promise for immunotherapy. CTLA4Ig (abatacept), a soluble version of the T cell-expressed membrane receptor CTLA-4, is approved for the treatment of rheumatoid arthritis. Like natural CTLA-4 molecules, CTLA4Ig ligates B7-1 and B7-2 on antigen presenting cells, preventing CD28-mediated costimulation of T cells. However, CTLA4Ig can also prevent ligation of CTLA-4, potentially blocking vital inh...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Jansson, A More by this author
Journal:
Molecular immunology
Volume:
49
Issue:
3
Pages:
527-536
Publication date:
2011-12-05
DOI:
EISSN:
1872-9142
ISSN:
0161-5890
URN:
uuid:38dcefe8-c4e6-4766-a910-09bb8fa88667
Source identifiers:
216478
Local pid:
pubs:216478

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP